



(51) International Patent Classification:

A61K 31/58 (2006.01) *A61P 35/04* (2006.01)*A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2023/013116

(22) International Filing Date:

15 February 2023 (15.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/315,240 01 March 2022 (01.03.2022) US

63/425,839 16 November 2022 (16.11.2022) US

(71) Applicant: PROPELLA THERAPEUTICS, INC.

[US/US]; 480 Hillsboro Street, Suite 130A, Pittsboro, North Carolina 27312 (US).

(72) Inventors: SHARP, Matthew J.; c/o Propella Therapeutics, Inc., 480 Hillsboro Street, Suite 130A, Pittsboro, North Carolina 27312 (US).

MOORE, JR., William R.; c/o Propella Therapeutics, Inc., 480 Hillsboro Street, Suite 130A, Pittsboro, North Carolina 27312 (US).

(74) Agent: LIU, Xiaoxiang; Nixon & Vanderhye P.C., 901 North Glebe Road, 11th Floor, Arlington, Virginia 22203-1808 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: ABIRATERONE DECANOATE PRODRUGS AND USE IN THERAPY



(57) **Abstract:** Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a human subject having a sex hormone-dependent or androgen receptor driven disease or disorder, such as a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, and/or a syndrome due to androgen excess.

[Continued on next page]

Published:

— with international search report (Art. 21(3))